Long Non-Coding RNA PVT1 Promotes Doxorubicin Resistance by Inhibiting Ferroptosis in Breast Cancer
Breast Cancer: Targets and Therapy · 2026-07 · Volume 18 · 1-15
DOI: 10.2147/bctt.s583235 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer: Targets and Therapy, 2026-07. Verfasst von Dan Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014…. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
There is growing evidence that long non-coding RNAs (lncRNAs) play crucial roles in cancer progression and therapy. Our previous study showed that the lncRNA plasmacytoma variant translocation 1 (PVT1) regulates tumor growth and metastasis in breast cancer (BC). As a conventional chemotherapeutic drug, doxorubicin (DOX) resistance continues to be a major challenge in BC treatment. This study aimed to explore the role and underlying mechanism of PVT1 in doxorubicin-resistant BC.
Methods
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blotting (WB) were carried out to detect gene and protein expression levels. The extent of ferroptosis was measured based on the cellular glutathione (GSH) levels and total or lipid reactive oxygen species (ROS) levels. An in-situ tumor implantation model in nude mice was employed to validate the mechanism in vivo. Transcriptome analysis was conducted to identify downstream target genes.
Results
This study found that PVT1 was highly expressed in the plasma of drug-resistant patients and drug-resistant cell lines. Silencing PVT1 reduced cellular glutathione level, increased reactive oxygen species (ROS) and lipid peroxidation (LPO), while ferroptosis inhibition in rescue experiments partially reversed the oxidative stress. In-vivo study confirmed that silencing PVT1 increased the sensitivity of BC cells to doxorubicin treatment. Transcriptomic sequencing revealed that solute carrier family 3 member 2 (SLC3A2) was the most potential target gene of PVT1, which was confirmed in PVT1-silenced cell models.
Conclusion
Mechanistically, PVT1 increased SLC3A2 expression, thus inhibiting ferroptosis and promoting doxorubicin resistance in BC, indicating that PVT1 could be a promising therapeutic target for doxorubicin-resistant BC patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Laboratory, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, People's Republic of China.
- Cancer Research Institute of Wuhan, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, People's Republic of China.
- Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, People's Republic of China.
ORCID-Profile: Zheqiong Tan, Zhongxin Lu
Zitieren
APA
Zhao, D., Tan, Z., Chen, W., Liu, S., Wu, T., Li, X., Xiang, Y., Wang, H., & Lu, Z. (2026). Long Non-Coding RNA PVT1 Promotes Doxorubicin Resistance by Inhibiting Ferroptosis in Breast Cancer. Breast Cancer: Targets and Therapy, Volume 18, 1-15. https://doi.org/10.2147/bctt.s583235
Vancouver
Zhao D, Tan Z, Chen W, Liu S, Wu T, Li X, et al. Long Non-Coding RNA PVT1 Promotes Doxorubicin Resistance by Inhibiting Ferroptosis in Breast Cancer. Breast Cancer: Targets and Therapy. 2026;Volume 18:1-15. doi:10.2147/bctt.s583235
BibTeX
@article{Zhao2026,
author = {Zhao, Dan and Tan, Zheqiong and Chen, Weiqun and Liu, Shuiyi and Wu, Tangwei and Li, Xiaoyi and Xiang, Yuan and Wang, Hui and Lu, Zhongxin},
title = {Long Non-Coding RNA PVT1 Promotes Doxorubicin Resistance by Inhibiting Ferroptosis in Breast Cancer},
journal = {Breast Cancer: Targets and Therapy},
year = {2026},
volume = {Volume 18},
pages = {1--15},
doi = {10.2147/bctt.s583235}
}
EUVIMED